[1] Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

[2] Treatment of bubonic plague with sulfonamides and antibiotics

[3] Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

[4] Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

[5] Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

[6] Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update